Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 7;15(1):78.
doi: 10.1186/s12969-017-0206-9.

Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis

Affiliations
Review

Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis

Gerd Horneff et al. Pediatr Rheumatol Online J. .

Abstract

Objective: Several effective pharmacologic treatment options for polyarticual juvenile idiopathic arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, the German Society of Pediatric Rheumatolgy has established a commission to develop consensus "Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND)" to harmonize diagnostic and treatment approaches for new-onset JIA in Germany.

Methods: A set of definitions for in- and exclusion, diagnostic workup, parameters for the evaluation of disease activity criteria, therapeutic options, medication dosing, monitoring recommendations, _targets, definitions of a therapy failure and four therapeutic algorithms developed by a working group were agreed by web based survey to which all members of the GKJR have been invited. A final protocol with 4 consensus treatment plans (CTP) was agreed in a face-to-face consensus conferences employing modified nominal group technique.

Results: The initial 17 definitions and recommendations for new-onset polyarticular JIA agreed by the working group reached >80% agreement in a web survey in 68 German paediatric rheumatologist. Four CTPs were developed based on treatment strategies for the first 12 months of therapy, as well as definitions for clinical and laboratory monitoring. The CTPs include a step-up plan (nonbiologic Disease-modifying antirheumatic drug [DMARD] followed by a biologic), a combination plan (combination of nonbiologic and biologic after failure of initial DMARD), an intensive pulse corticosteroid scheme in parallel with a DMARD followed by combination therapy and a multiple corticosteroids joint injections strategy in a treat to _target approach. Step up will be guided by a treat to _target strategy to reach a JADAS-improvement at month 3, acceptable disease at month 6 or 9 and JADAS remission or at least JADAS minimal disease activity at month 12.

Conclusion: Standardized baseline work-up, disease activity evaluation and a definition of a treat to _target approach will result in better health outcomes for polyarticular JIA patients. Four CTPs were developed for new-onset polyarticular JIA, which coupled with data collection at defined intervals will be evaluated and improved to optimize management of polyarticular JIA. Harmonization of treatment will be the basis for future comparative effectiveness research.

Keywords: Polyarticular juvenile idiopathic arthritis; Treat to _target; Treatment.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable, there are no person’s data in any form.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Therapeutic algorithm with 4 equally applicable consensus treatment plans. Initial treatment with methotrexate is intended for all patients with the diagnosis of polyarticular JIA. Non-steroidal-antiinflammatory drugs (NSAID) and up to 4 intraarticular joint injections with Triamcinolone hexacetonid are facultative on the discretion of the physician. Efficacy and tolerability should be evaluated every 3 months. The existing therapy will be continued if the therapeutic goals have been achieved, but should be altered if these have not been achieved. The treatment goals formulated for month 3, 6, 9 and 12 become more stringent with duration of therapy. The selection of the biologics is the responsibility of the treating physician. The approval for age and weight should be considered. ABA = abatacept, ADA = adalimumab, ETA = etanercept, GOL = golimumab, TOC = tocilizumab

Similar articles

Cited by

References

    1. Petty RE. Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Rheumatol (Oxford) 1999;38:739–742. doi: 10.1093/rheumatology/38.8.739. - DOI - PubMed
    1. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342:763–769. doi: 10.1056/NEJM200003163421103. - DOI - PubMed
    1. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis in the biologic age. Rheum Dis Clin N Am. 2013;39:751–766. doi: 10.1016/j.rdc.2013.05.004. - DOI - PubMed
    1. Magnani A, Pistorio A, Magni-Manzoni S, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009;36(3):628–634. doi: 10.3899/jrheum.080560. - DOI - PubMed
    1. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic D, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Hamilton S, Johnson A, Huang B, Lovell DJ. Childhood arthritis and rheumatology research alliance.: trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–21. - PMC - PubMed

Substances

  NODES
INTERN 1
Note 1
twitter 2